The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

American Health Packaging Inc. is initiating a drug recall to the **RETAIL LEVEL for AHP Rifampin Capsules USP, 300 mg, 100 UD; Carton NDC#: 60687-586-01 (Individual Dose NDC: 60687 586 11)** for the lot listed below:

Product Description	AHP Lot No.	Expiration Date	Ship Dates of Product
AHP Rifampin Capsules USP, 300 mg, 100 UD Carton NDC#: 60687-586-01 **(Individual Dose NDC: 60687-586-11)**	1007805	12/31/2023	04/20/2022 to 05/10/2022

Reason for Recall

This recall is being initiated in support of the recall by the manufacturer (Lupin Pharmaceuticals, Inc.) dated December 12, 2022, which included lots that were repackaged by American Health Packaging.

Lupin stated that "These lots are being recalled due to an out of specification ("00S") result observed in related substance testing during long term stability study in lot A200171. In view of the maximum daily dose and the half-life at this dose, along with the potential bioavailability of this drug any potential impact of the out-of-specification impurities may be negligible in patients."

Health Hazard Evaluation

Rifampin is a semisynthetic antibiotic derivative of rifamycin SV. Rifampin is indicated in the treatment of all forms of tuberculosis. Rifampin is indicated for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx.